Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II study of CSTD002-NK in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) undergoing haploidentical hematopoietic stem cell transplantation (HSCT)

Trial Profile

A phase II study of CSTD002-NK in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) undergoing haploidentical hematopoietic stem cell transplantation (HSCT)

Planning
Phase of Trial: Phase II

Latest Information Update: 08 Oct 2018

At a glance

  • Drugs CSTD002 NK (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors CytoSen Therapeutics
  • Most Recent Events

    • 08 Oct 2018 New trial record
    • 27 Sep 2018 According to a CytoSen Therapeutics media release, the company plans to initiate enrollment of the study in USA in first half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top